Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio Nov 14, 2024 04:15PM
Akari Therapeutcis (AKTX): Skeptical Of Coversin In PNH - Chardan Aug 11, 2017 06:59AM
Chardan Capital Markets Upgrades Akari Therapeutics (AKTX) to Neutral May 31, 2017 04:55AM
Chardan Capital Markets Reiterates Sell Rating and $6.50 PT on Akari Therapeutcis (AKTX); 'Weak Efficacy for Coversin in the Ph2 PNH COBALT Trial' Apr 24, 2017 12:01PM
Akari Therapeutics (AKTX) PT Raised to $6.50 at Chardan Capital Markets; 'Skepticism on Coversin in PNH' Apr 17, 2017 05:55AM


Jul 11, 2016 07:33AM Chardan Capital Markets Starts Akari Therapeutics (AKTX) at Sell